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For the past 50 years, the route of inhalation has been utilized to administer therapies
to treat a variety of respiratory and pulmonary diseases. When compared with other
drug administration routes, inhalation offers a targeted, non-invasive approach to
deliver rapid onset of drug action to the lung, minimizing systemic drug exposure and
subsequent side effects. However, despite advances in inhaled therapies, there is still
a need to improve the preclinical screening and the efficacy of inhaled therapeutics.
Innovative in vitro models of respiratory physiology to determine therapeutic efficacy
of inhaled compounds have included the use of organoids, micro-engineered lung-on-
chip systems and sophisticated bench-top platforms to enable a better understanding
of pulmonary mechanisms at the molecular level, rapidly progressing inhaled therapeutic
candidates to the clinic. Furthermore, the integration of complementary ex vivo models,
such as precision-cut lung slices (PCLS) and isolated perfused lung platforms have
further advanced preclinical drug screening approaches by providing in vivo relevance.
In this review, we address the challenges and advances of in vitro models and
discuss the implementation of ex vivo inhaled drug screening models. Specifically, we
address the importance of understanding human in vivo pulmonary mechanisms in
assessing strategies of the preclinical screening of drug efficacy, toxicity and delivery
of inhaled therapeutics.
Keywords: drug efficacy, drug delivery, drug toxicity, inhalation therapy, isolated perfused lung, lung-on-chip,
organoid, precision-cut lung slices
INTRODUCTION
Respiratory diseases are among the leading causes of mortality worldwide, with chronic obstructive
pulmonary disease (COPD), lung infections (viral and bacterial), lung cancer and tuberculosis all
listed in the top 10 causes of death (World Health Organisation [WHO], 2019a,b). Respiratory
diseases impose an immense global health burden, with an estimated 1 billion people suffering
from either acute or chronic conditions that result in upwards of 4 million deaths annually (World
Health Organisation [WHO], 2014). Treatment of respiratory diseases relies on a variety of drug
administration routes, however, not all routes are effective for disease or symptomatic relief.
For example, when treating lung cancer, anti-cancer therapeutics are commonly administered
systemically, resulting in low drug concentrations at the tumor site, reduced efficacy and multiple
negative systemic side effects (Palumbo et al., 2013). Thus, a more targeted approach to the delivery
and administration of anti-cancer drugs for lung cancer patients may increase therapeutic benefit
and also quality of life. Whereas, oral and intravenous drug administration of high dose antibiotics
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and anti-inflammatory agents are commonly used to treat
COPD, cystic fibrosis, pulmonary oedemas, and respiratory
infections. However, both of these administration routes require
the drug to be pre-processed by either liver or kidney and as
a result, sustained long-term treatment strategies often cause
liver/kidney toxicity and failure (Ditchfield et al., 2018). As
such, a targeted delivery approach that deposits drugs directly
within the lung (via inhalation) will distribute optimal and
effective drug concentrations to the diseased site, minimize
systemic drug exposure by negating any negative side effects,
and thereby improve therapeutic efficacy, patient outcomes and
patient quality of life (Borghardt et al., 2018).
The complex anatomical structure and branching of the lung
present a unique challenge when attempting a targeted drug
delivery approach. The airways also contain several biological
barriers and properties that can limit drug uptake (transport,
absorption) and subsequent efficacy (Ruge et al., 2013). Following
inhalation, drugs deposited in the lung are subject to removal
by the natural clearance mechanisms of the epithelium; goblet
cells secrete a mucous layer to line the airways, and ciliated cells
rapidly beat in a coordinated, metachronous fashion to move the
mucous-trapped drug particle up, and out of the airway (Eliezer
et al., 1970). While, drugs deposited in lower lung regions, for
example in the alveolar space, are engulfed and removed by
resident alveolar macrophages (Wanner et al., 1996; Ruge et al.,
2013). However, once a drug is successfully deposited within
an airway, a new challenge arises, as the epithelial cells that
line the bronchial tree form tight junctions and it is these tight
junctions that limit drug uptake and therefore therapeutic efficacy
(Ghadiri et al., 2019). Importantly, however, it is not just the
structural, physiological and biological properties of the lung
that present challenges for inhaled therapies, the physiochemical
and pharmacokinetic characteristics of the drug also need to be
taken into account.
The physiochemical attributes of an inhaled drug interact with
the biological properties of a lung to determine the deposition
site, mechanism of action and therapeutic efficacy. The size of
an aerosolized drug particle plays a pivotal role in determining
the exact deposition site within the lung with particles of an
aerodynamic diameter of 5–10 µm depositing in the larger
airways, while particles less than 2 µm in diameter can be
targeted to the bronchoalveolar and deep lung alveolar regions
(Davies and Muir, 1966; Yeh et al., 1976; Lippmann et al.,
1980). Particles with an aerodynamic diameter smaller than
0.5 µm can theoretically be delivered to the alveolar space,
however, the majority of particles are immediately exhaled
following inhalation due to their small size (Davies and Muir,
1966; Yeh et al., 1976; Lippmann et al., 1980). In order
to evade the aforementioned clearance mechanisms of the
airways, inhaled therapeutics are engineered with the appropriate
surface chemistry to avoid adhesion to the mucosal layer and
yet small enough for deposition beyond the large airways
(Lippmann et al., 1980).
To appropriately determine key parameters of inhaled
therapies (aerodynamic performance, pharmacodynamics and
pharmacokinetics), in vitro lung models have been developed,
validated and characterized to be used as preclinical screening
tools. One of the key objectives for these in vitro research
models is to mimic the structural and biological properties
of the in vivo human lung environment to better replicate
therapeutic exposure, deposition and efficacies. It is important
to note that the translation of results from human in vitro
models to in vivo animal (namely, rodent and pig) experimental
results have proved limited and is hypothesized to be due to the
anatomical, physiological and pathophysiological differences of
human and animal lungs (Ware, 2008; Aun et al., 2017). In this
review, we address the challenges and advances in in vitro and
ex vivo respiratory research models when evaluating therapeutic
efficacy of inhaled therapeutics in a preclinical setting to ensure
successful translation to the clinic. Specifically, we discuss
the implementation of progressive lung models (respiratory
organoids, lung-on-chip platforms) and sophisticated bench-
top approaches to evaluate inhaled drug delivery, efficacy and
potential cytotoxicity.
CONVENTIONAL RESPIRATORY in vitro
CELL MODELS
Mimicking the Heterogeneity of the
Respiratory Microenvironment
The respiratory epithelium lines the airways and provides
the principal physical barrier to transport and absorption of
foreign particles, including inhaled therapies. The bronchial
epithelium is composed of a heterogeneous mix of cells that
stem from distinctive lung progenitor cells and can self-renew
and differentiate into goblet, ciliated, or basal cells (Eliezer et al.,
1970; Wanner et al., 1996; Ruge et al., 2013; Li et al., 2015). As
mentioned previously, these differentiated epithelia cells protect
the respiratory tract from foreign irritants such as smoke and
dust, but also drug particles (Wanner et al., 1996). Epithelial
cells form tight junctions between the neighboring epithelial
cells to seal off the paracellular space between cells, regulating
the influx and efflux of xenobiotics, but also the release of
inflammatory mediators following inhalation of foreign agents,
irritants and particulates to activate and recruit immune cells
(Madara, 1998). Thus, mimicking these important biological
barriers and properties in vitro has become an important tool
when validating the appropriateness of a cell-based model.
Numerous human bronchial epithelial cell lines have been used to
recapitulate both healthy and diseased respiratory environments
in vitro to specifically evaluate drug transport in response to the
biological barriers of the epithelium (16HBE16o-, NuLi-1, and
BEAS-2B (healthy human bronchial epithelial cells; Forbes et al.,
2003; Garcia-Canton et al., 2013; Monnappa et al., 2016), Calu-3
and NCI-H441 (lung adenocarcinoma; Ong et al., 2011; Salomon
et al., 2014); and CuFi-1 and CuFi-5 (cystic fibrosis; Molina et al.,
2015; Sheikh et al., 2020).
Progress and Limitations of in vitro
Air-Liquid Interface Models
To recapitulate luminal airflow of the respiratory system
in vitro, an air-liquid interface (ALI) culture system has been
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implemented. Briefly, cells are first seeded onto the semi-
permeable membrane of a Transwell support and both the
apical (upper; cell) and basolateral (bottom; media) chambers are
submerged in culture medium. When cell confluency is reached,
media from the apical chamber removed, exposing the cultured
cells to air and therefore establishing the ALI. Importantly,
exposing cells to the air forces the cells to differentiate, secrete
mucus and establish tight junctions, mimicking the in vivo
respiratory environment. Furthermore, ALI respiratory models
allow in vivo inhaled drug exposure conditions to be replicated
by subjecting drug particles to the differentiated cell layer of
the model. As such, ALI culture models provide a unique
in vitro platform to mimic drug deposition onto the respiratory
epithelial surface allowing downstream drug transport, efficacy
and cytotoxicity studies to be performed (Grainger et al., 2006;
Ong et al., 2011; Salomon et al., 2014).
Formation of the key biological parameters, namely tight
junctions and differentiation is required for a successful ALI
culture model to appropriately assess drug uptake, solute
permeability and transport mechanisms. Various immortalized
respiratory cell lines, including Calu-3, A549, 16HBE, NuLi-
1, CuFi-1, and NCI-H441, have all been shown to form tight
junctions and/or produce mucous under specific and appropriate
ALI culture conditions (Grainger et al., 2006; Ong et al., 2011;
Salomon et al., 2014; Faura Tellez et al., 2016; Latvala et al.,
2016; Sheikh et al., 2020). However, many cell lines are limited
in their ability to functionally recapitulate the in vivo respiratory
epithelium. For example, the A549 cell line is unable to form
functional tight junctions as A549 cells show reduced expression
of the seal-forming proteins, claudin-3, -4, and -5 (Ren et al.,
2016), while the Calu-3 cell line is unable to produce functional
ciliary activity (Kreft et al., 2015). As a result, ALI culture
systems have progressed to use primary human respiratory
epithelial cells as primary cells can generate ciliated cells, mucus
secretions and form tight junctions to better represent the
in vivo respiratory epithelium (Pezzulo et al., 2011; Wang et al.,
2018). However, there are several caveats to the use of primary
epithelial cells as these cells have a finite population doubling
and obtaining primary human respiratory epithelial cells from
commercial sources is often expensive. As an alternative, primary
bronchial epithelial cells can be harvested and expanded from
deceased or transplanted human lungs, but this requires ethics
approval and is a labor- and skill-intensive protocol. Despite these
limitations, primary respiratory epithelial ALI culture models
have been used to recapitulate in vivo airway epithelia as a
biologically relevant in vitro drug screening platform (Ong
et al., 2016). ALI culture systems have been heavily reviewed
in the literature and have delivered highly impactful research
outcomes (Movia et al., 2018; Upadhyay and Palmberg, 2018)
however, the use of in vitro ALI models to determine toxicity,
delivery and efficacy of inhaled therapeutics requires greater
physiological and anatomical relevance. Specifically, in vitro
respiratory models that implement breathing mechanics, aerosol
deposition, and the co-culture of different cell types allow
greater mechanistic and efficacious insights of novel inhalable
therapeutic compounds. Thus, in vitro models that consider the
biological and physiological diversity of the respiratory system
provide an appropriate preclinical screening tool to determine
how the respiratory microenvironment dictates the therapeutic
response of inhaled agents (Table 1).
in vitro EXPERIMENTAL MODELS THAT
PHYSIOLOGICALLY MIMIC THE
RESPIRATORY SYSTEM TO SCREEN
INHALED THERAPIES
To accurately investigate drug delivery, efficacy, and toxicity of
inhaled therapies, in vitro experimental models that accurately
resemble the in vivo physiology are crucial research tools. As such,
in vitro experimental models have advanced beyond standard
ALI monoculture methods to now include the mechanical
and physiological parameters of breathing (the cyclic tissue
stretch that occurs during inhalation and exhalation) that
regulate airflow and pressure, the role of the extracellular
matrix (ECM), and multiple cell types (alveolar, endothelial
or smooth muscle cells etc.). To determine the preclinical
success of an inhaled therapy, therapeutic dosage, efficacy and
toxicity must be evaluated in a model(s) that aptly replicate the
physiological parameters that influence in vivo drug transport
mechanisms. Importantly, drug deposition in a specific lung
region must first be inhaled via the mouth (oral pharyngeal)
and then delivered to the airways (mouth-to-airway transit) and
therefore is an important characteristic to replicate and include
in preclinical screening models for inhaled therapies. Thus, the
use of sophisticated 3-dimensional (3D) experimental models
[organoids (Figure 1) and chip-based platforms (Figure 2)]
and devices that model mouth-to-airway transit [Andersen
Cascade impactor (ACI) (Figure 3), next-generation impactor
(NGI) (Figure 4), and twin stage impinger (TSI) (Figure 5)]
have advanced the preclinical screening capabilities of novel
inhaled therapies.
Respiratory Organoids Recreate the
3-Dimensional Microenvironment of
Airways to Evaluate Drug Efficacy and
Toxicity
Respiratory organoids are 3D tissue-engineered culture systems
capable of mimicking essential structural aspects of airways
to screen drug pharmaceutical safety and efficacy (Jung
et al., 2019; Liu et al., 2020). Unlike ALI monoculture
models, respiratory organoids physiologically represent the 3D
respiratory airway lumen microenvironment by promoting
the growth and differentiation of multiple cell types to
mimic the diverse structural branching present in airways
(Barkauskas et al., 2017; van der Vaart and Clevers, 2020).
Respiratory organoids are generated from primary lung and/or
pluripotent stem cells that self-aggregate to form spheroids
and then embedded within a complex mixture of extracellular
matrix (ECM) proteins (collagens, laminin, and fibronectin)
(Barkauskas et al., 2017; Chen et al., 2017; Leeman et al., 2019).
Exposure to the ECM proteins provides the architectural and
physiological support for sustained cell growth, differentiation,
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cell-cell and cell-matrix signaling pathways that encourages the
correct spatially organization of heterogenous cell populations
(epithelial, alveolar, mesenchymal cells) to generate luminal
growth within the organoid (Figure 1A; Jacob et al., 2017; Tan
et al., 2017; Miller et al., 2019). Therapeutic compounds are
microinjected directly into the lumen of the organoid (Hill et al.,
2017), organoids are integrated within microfluidic devices (via
drug diffusion in solution) (Jung et al., 2019) or implanted
within in vivo models (patient-derived xenografts) (Figure 1B;
Tan et al., 2017; Berkers et al., 2019; Kim et al., 2019; Takahashi
et al., 2019) to provide a physiologically relevant in vitro drug
screening platform.
Respiratory organoids have been used to model the
specific characteristics and physiological properties numerous
respiratory diseases including to cystic fibrosis (Berkers et al.,
2019; Dekkers et al., 2013; Liu et al., 2020), fibrosis (Strikoudis
et al., 2019), viral and bacterial infections (Chen et al., 2017;
Hill et al., 2017; Paolicelli et al., 2019), and lung cancer (Jung
et al., 2019; Kim et al., 2019; Takahashi et al., 2019). The delivery
of novel preclinical drug compounds to organoid models of
respiratory diseases to determine therapeutic efficacy and
cytotoxicity has been achieved in a variety of experimentally
diverse setups. Hill et al. (2017) delivered drugs directly to the
lumen by microinjection (using thin wall glass capillaries) to
determine patient-specific drug transport, permeation across
an epithelial barrier, efficacy, and toxicity, while preventing
luminal contamination of the external growth media. Organoid
integration within microfluidic devices has achieved drug
delivery under flow conditions, mimicking the pulmonary
system (Jung et al., 2019). By implementing flow conditions,
a stable supply of nutrients and oxygen is delivered to the
organoid but also allowed drug-containing medium to be
delivered to the organoid thus, mimicking the diffusion uptake
process of systemically delivered drugs. The study by Jung et al.
(2019) developed patient-derived lung cancer organoids loaded
within a microfluidic chip device to allow clinically relevant
chemotherapeutic sensitivity under physiologically relevant flow
conditions and determining safe therapeutic concentrations at
the preclinical level.
Respiratory organoid models have also been developed to
advance personalized medicine, especially for those diseases with
high phenotypic and genetic variability including cystic fibrosis
(Dekkers et al., 2013; Berkers et al., 2019) and lung cancer
(Kim et al., 2019; Kondo and Inoue, 2019). Kim et al. (2019)
derived lung cancer organoids from 36 patient tumor tissues of
five different histological subtypes to determine individualized
patient sensitivities, and in some cases previously unknown
resistance to specific chemotherapeutics was found. The direct
implantation of organoids in vivo, typically mice (known as
PDX models), recapitulate the structural hallmarks of cancer
tissue and maintain both genetic and histological characteristics
of cancer. While drug delivery directly to the luminal space
of the organoid is currently unavailable in these PDX models,
drugs can be administered via intraperitoneal injection and the
organoid then harvested for further pharmacodynamic and bio-
pharmacokinetic analyses. Cystic fibrosis organoids been derived
from patients with diverse genetic mutations and treatment
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 4 October 2020 | Volume 8 | Article 581995
fbioe-08-581995 October 19, 2020 Time: 19:14 # 5
Cidem et al. Advancements in Inhalation Drug Screening
FIGURE 1 | (A) Schematic overview of methods for the generation of respiratory organoid cultures derived from primary lung cells. (B) The varying modes of drug
treatment delivery in an organoid model (made in ©BioRender - biorender.com).
FIGURE 2 | Schematic representation of the microfluidic lung-on-chip (LOC) system. Cross-section through the LOC model displaying the upper chamber consisting
of human lung epithelial cells and the lower chamber consisting of pulmonary endothelial cells divided by a thin porous membrane. Side vacuum channels stretch
out the membrane and mimic in vivo breathing-like forces (adapted from Huh et al., 2010 and made in ©BioRender - biorender.com).
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FIGURE 3 | Diagrammatic rrepresentation of a modified Anderson Cascade Impactor (mACI) with the incorporation of Snapwell or Transwell inserts embedded with
respiratory cell lines at the air-liquid interface (ALI). Airflow is maintained at a controlled flow rate and generated via vacuum flow on the opposite end of the mACI to
simulate airflow and allow for the assessment of mouth-to-airway transit of drug particles. Evaluation of aerosolized drug particle deposition, transport and
absorption across the cell epithelia is determined through assessing inserted Transwells.
FIGURE 4 | A modified Next Generation Impactor (mNGI) with the implementation of Transwell inserts embedded with respiratory cells on stages 3, 5, and 7 at the
lower panel of the apparatus. Airflow is maintained at a controlled flow rate and generated via vacuum flow on the opposite end of the mNGI allowing for the
assessment of mouth-to-airway transit of drug particles. Evaluation of aerosolized drug particle deposition, transport and absorption across the cell epithelia is
determined through assessing inserted Transwells.
regimens have been developed to better predict therapeutic
outcomes of individual patients (Dekkers et al., 2013; Berkers
et al., 2019). Drugs administrated to the culture media of
patient-derived cystic fibrosis organoids showed that this was
a powerful predictor of therapeutic outcomes and patient
responses to single and combination drug treatment regimens for
a personalized medicine approach (Dekkers et al., 2013). Thus,
patient-derived organoids offer a unique in vitro approach to
developing personalized, targeted inhalable therapies as they take
into account patient-specific phenotypic differences (i.e., mucous
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FIGURE 5 | Schematic representation of a modified Twin Stage Impinger (mTSI) with the integration of ALI cell culture insert at the base of stage 2 enabling
aerosolized drugs to be deposited directly at the respiratory epithelia to better mimic in vivo biopharmaceutical processes of particle deposition and absorption.
production in cystic fibrosis patients or genetic mutations in lung
cancer patients) known to impact drug uptake.
Respiratory organoid models serve as a tool to study disease-
relevant and physiologically relevant cell-cell interactions when
testing the therapeutic efficacy and toxicity of novel drug
compounds. However, respiratory organoids lack not only the
breathing mechanics that regulate airflow and pressure but
also the anatomical structure that gives rise to the mouth-
to-airway transit, both vital in determining the aerodynamic
performance, pharmacodynamics and deposition of an inhaled
therapy. Thus, while organoids are a novel and advantageous
in vitro tool, they may not be the ideal research tool for
screening therapeutic efficacy and toxicity of inhaled compounds
as breathing mechanics and lung anatomy are vital to properly
assessing the therapeutic efficacy of inhaled compounds.
Chip-Based Devices Mimic the
Physiological and Mechanical Properties
of a Lung to Better Predict Therapeutic
Outcome of Inhaled Therapies
Organ-on-a-chip-based devices have been engineered to
appropriately mimic the physiological and mechanical
parameters that regulate and influence, organ homeostasis
and function. In terms of the respiratory system, lung-on-chip
(LOC) devices simulate the diverse physiological and mechanical
parameters of an in vivo respiratory environment by replicating
the in vivo breathing mechanics (the cyclic stretch of inhalation
and exhalation), airflow and air pressure dynamics, cellular
heterogeneity and vascular flow rates. At the cellular level,
it is known that exposure to mechanical stressors, including
stretch and/or changes to airflow and fluid shear stress induce
proliferation (Gudipaty et al., 2017), differentiation (Edwards,
2001) and cell function (Ke et al., 2019), highlighting the
importance of integrating mechanical stress when mimicking an
in vivo environment. Thus, LOC devices have permitted in vitro
investigations to determine the behavior of inhaled therapies
(aerodynamic performance, bio-pharmacokinetics, therapeutic
efficacy and toxicity) and how physiological and mechanical
in vivo parameters impact drug uptake.
LOC devices are 3D, micro-fabricated, microfluidic devices
that feature two separate chambers [an apical (top) and a
basal (bottom) chamber] separated by a thin porous membrane
that supports the growth, maturation and/or differentiation of
distinct cell types on each side of the membrane (Figure 2).
Importantly, each chamber can be subjected to independent
dynamic flow conditions (i.e., airflow and liquid flow conditions),
to better replicate the in vivo interplay between cell-cell, cell-
matrix and cell-mechanical forces in vitro (Huh et al., 2010;
Benam et al., 2016). The first LOC device was published
by Huh et al. (2010) and reproduced key physiological and
mechanical parameters of the human alveolar-capillary interface
with alveolar cells seeded on the apical surface of the membrane
and exposed to air with variable flow and pressure rates to
simulate breathing. Pulmonary endothelial cells were applied
to the basal surface of the membrane and subjected to the
liquid-filled chamber under dynamic perfusion to mimic blood
flow (Huh et al., 2010). The LOC device is uniquely fitted
with a vacuum chamber at either side of the apical and
basolateral chambers (Figure 2) to simulate the mechanical
stretch that occurs during breathing. Taken together, LOC
devices provide a more sophisticated ALI model that allows
researchers to mimic the in vivo pulmonary interactions of
the alveolar air space and blood vessels while integrating
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 7 October 2020 | Volume 8 | Article 581995
fbioe-08-581995 October 19, 2020 Time: 19:14 # 8
Cidem et al. Advancements in Inhalation Drug Screening
mechanical stimuli to better model drug deposition and
therapeutic studies.
LOC devices model the biological, physiological and
pathophysiological characteristics of the human respiratory
system and therefore, have been used to assess cellular
response(s) following exposure to therapeutic stimuli under
dynamic flow conditions. COPD LOC devices have been
engineered to measure cellular inflammatory responses to
novel anti-inflammatory compounds delivered via the vascular
channel (basal chamber), replicating systemic drug delivery
(Benam et al., 2016). LOC devices have also been used to model
cellular responses to inhaled nanoparticles (delivered apically,
in solution) revealing that alveoli cells under cyclic mechanical
strain show enhanced cytotoxicity and inflammation in response
to nanoparticles in comparison to conventional 2D culture
systems that do not possess mechanical force regimens (Huh
et al., 2010). Interestingly Huh et al. (2010) also identified that
cyclic strain enhanced epithelial and endothelial uptake and
therapeutic efficacy of nanoparticles, confirming the importance
of integrating mechanical parameters in in vitro models.
Chip-based devices have diversified from the single organ
on a chip (i.e., LOC) to now include body-on-a-chip (BOC)
[sometimes referred to as multi-organ-on-a-chip (MOC)]
technologies that can be used to predict the complex organ
cross-talk that occurs during drug delivery, metabolism and
toxicity (both local and systemic). Concerning the respiratory
system, exposure to inhaled therapies and/or toxicants enhances
the complexity and physiological relevance of multiple tissue
responses, including liver and kidney. The co-culture of 3D
respiratory organoids with liver spheroid cultures integrated
within a single chip device saw the arrival of the lung/liver-
on-a-chip BOC device (Bovard et al., 2018). By incorporating
the liver model, Bovard et al. (2018) were able to test both
the toxicity of inhaled compounds and metabolites and further
monitor the toxicity profile of the administered compounds in
both organs in vitro (Bovard et al., 2018). Similarly, Miller et al.
(2020) engineered a multi-organ breast cancer BOC device to
compare the efficacy and toxicity of inhaled and/or intravenously
delivered anticancer drug, curcumin. For physiological relevance,
the breast cancer BOC device integrated both the liver (complete
with recirculating flow), and the lung (including ALI and
breathing mechanics to replicate gas exchange, and contraction
and expansion) (Miller et al., 2020). Interestingly, curcumin
was only found to significantly induce lung toxicity when the
device was under static conditions but when breathing mechanics
were added to the device, lung cell viability was not affected.
Taken together, both the Bovard et al. (2018) and Miller et al.
(2020) studies have highlighted the importance of appropriately
mimicking the in vivo physiological environment to determine
therapeutic efficacy and cytotoxicity but also determine the
involvement and cross-talk of multiple organs.
LOCs and BOCs offer tremendous potential to be utilized
as a dynamic inhaled drug screening platform, with future
opportunities to integrate clinically relevant aerosolized
inhalation therapy exposure systems as the current mode of
drug treatment relies on the direct delivery of solubilized drug
into the apical chamber. While LOCs and BOCs mimic the
mechanical strain of breathing and the respiratory air-liquid
microenvironment, these platforms are not optimized to study
“real” aerosol characteristics and interactions during mouth-
to-airway transit of drug particles. Importantly, the anatomical
and physiological elements of the human respiratory system
(including the upper airways: mouth, pharynx and larynx and
the lower airways: bronchial branching, mucosal lining, and
humidity) need be integrated within in vitro models to allow for
greater clinical relevance when assessing inhalation therapies.
In vitro Mouth-to-Airway Transit Delivery
Models
The anatomical and physiological elements of the human
respiratory system (including bronchial branching, mucosal
lining, and humidity) need be integrated within in vitro models
to allow for greater clinical relevance. Both the upper and
lower airways contribute to the challenges that govern targeted
delivery and disposition of inhaled particles of therapeutic
concentration at a specific region of the lung (bronchial
epithelium, alveolar space, smooth muscle) can be problematic
as significant concentrations of the drug is lost in the upper
airways, i.e., during mouth-to-airway transit (Ong et al., 2015).
Furthermore, mouth-to-airway transit of inhaled compounds
dictates the aerosol deposition at specific anatomical lung
regions, an important characteristic to model in vitro for in vivo
relevance. To model aerosol behavior in a physiological and
anatomical realistic environment, various impactor technologies
(Anderson Cascade impactor, next-generation impactor, twin
stage impinger) have been developed and then modified to
couple with cell culture models, allowing greater in vivo
relevance of drug deposition and therapeutic efficacy in vitro.
While previous reviews have extensively described the use of
impactor technologies as inhalation therapy models for drug
delivery (Marple et al., 2003a,b, 2004; Haghi et al., 2014a),
this section of our review will focus on the advances in
these technologies. Conventional in vitro impactor studies have
utilized ALI culture models to measure the permeability of a
drug solution once pipetted onto the cell layer but overlook
the important physiochemical characteristics of aerosolized
particles (size, surface chemistry and morphology) that affect
in vivo drug deposition, therapeutic efficacy and therefore
clinical relevance. Thus, attempts have been made to modify
conventional impactors to study deposition and permeability of
aerosolized drugs on respiratory cell culture models.
Cascade Impactors
Cascade impactors are multi-staged in vitro tools used to
characterize aerosol performance at different regions of the lung.
Both the Anderson Cascaded Impactor (ACI; Figure 3) and
the Next Generation Impactor (NGI; Figure 4) designed to
measure the size distribution and concentration of an aerosolized
sample under flow conditions. Each stage of a cascade impactor
corresponds to a specific region of the lung and therefore the
size of the particle dictates the region that the particle can
be deposited. For example, Stage 0 corresponds to the mouth
and typically allows only those particles with a diameter of
less than 10 µm to pass through (cascade) to the following
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stage. Stage 7 represents the alveolar space and will only
allow particles with a diameter of 0.4 µm to enter the stage.
Importantly, drug concentration can also be determined at each
stage thus, predicting the concentration of drug deposited at
specific lung regions.
The ACI is a vertical cascade apparatus and is the primary
method for characterizing aerosolized particle deposition of
inhaled compounds (Figure 3). Haghi et al. (2014b) developed
a modified ACI (mACI) that incorporated ALI models of Calu-3
cells inserted within the mACI at stages 4–7 that represented the
deep lung region (the base of the trachea to the alveolar space).
By integrating the ALI culture models within the ACI, deposition
and subsequent permeability of inhalable Ventolin (salbutamol
sulfate) and Qvar (beclomethasone dipropionate) formulations
were conducted with drug formulations delivered via an inhaler
device [known as a pressurized metered dose inhaler (pMDI)] to
provide for clinically relevant administration of inhaled therapies
(Haghi et al., 2014b). The mACI model presented in the Haghi
et al. (2014b) study demonstrated reproducible and similar
patterns of particle deposition when compared to an unmodified
ACI, confirming the mACI model as a reliable in vitro tool to
evaluate micro-particle deposition, permeability and therapeutic
efficacy on respiratory epithelia using a delivery system that
modeled mouth-to-airway drug transit.
The NGI is a horizontal cascade apparatus used to predict
in vivo drug behavior that has also been modified to include
an ALI cell culture model (mNGIs) able to determine aerosol
deposition and transport across cell epithelia (Shur and Price,
2016; van Rensburg et al., 2018; Kumar et al., 2020). mNGIs have
been engineered to deliver aerosolized particles under controlled
vacuum flow to ALI cultured Calu-3 cells at stages 2, 3, and 4
(van Rensburg et al., 2018) and stages 3, 5, and 7 (Kumar et al.,
2020), highlighting the versatility and adaptability of an mNGI
depending on a researchers needs. The mNGI has been utilized
to examine the uptake of a pMDI administrated aerosolized
glucocorticoid (anti-inflammatory) of various particle sizes to
determine how particle size influenced not only aerodynamic
performance, but also anti-inflammatory efficacy in vitro (Kumar
et al., 2020). Thus, modified cascade impactors are important
and valid in vitro drug screening tools, as the integration of cell-
based platforms (ALI cultured cells) permit investigations that
evaluate in vivo deposition of aerosol particles, cellular response
and therapeutic efficacy of novel inhaled compounds.
Twin Stage Impingers
The modern-day glass twin stage impinger (TSI) apparatus
allows aerosolized compounds to be delivered at a simulated
oropharynx (mid pharynx) and particles are then separated by
size throughout the two stages of the device (Figure 5). The
first stage of the TSI replicates the upper airways, while the
second stage resembles the lower airways. It is important to
note that the TSI does not fully simulate the mouth-to-airway
transit as the drug is delivered at the mid pharynx rather than
a simulated oral pharyngeal orifice however, the aerosolized
fraction that is delivered and collected in the first stage of the
TSI has been shown to positively correlate with drug amounts
collected in the mouth and throat (Hallworth and Westmoreland,
1987). Regardless, the TSI remains an important and widely used
in vitro tool to determine the aerodynamic performance of an
inhaled therapeutic as particle trajectories can be determined
to identify the site-specific deposition of an aerosolized drug
(Mendes et al., 2009). Similar to the mNGI and mACI, a modified
version of the TSI (mTSI) has integrated an ALI cell culture
model at the base of stage 2 (Figure 5) enabling aerosolized drugs
(delivered via a pMDI) to be deposited directly at the respiratory
epithelia to better mimic in vivo biopharmaceutical processes
(Figure 5; Grainger et al., 2012; Haghi et al., 2012; Ong et al.,
2014). The integration of a microfluidic device as a nebulization
platform for pulmonary drug delivery alongside a TSI has been
implemented in a study by Qi et al. (2009), demonstrating the
use of microfluidics as an efficient means to generate appropriate
aerosolized drug particles. A TSI was utilized to confirm the
mean aerosol diameter produced by the device, demonstrating
the high efficiency of drug particle delivery and the overall
viability of the microfluidic platform for inhalation therapy (Qi
et al., 2009). It would be of great interest to further enhance
and modify TSI models by incorporating alternative in vitro
cell culture systems (organoids, LOC/BOC devices etc.) to better
mimic the respiratory microenvironment for evaluating inhaled
drug particle transport, absorption and bio-pharmacokinetics.
The use of in vitro cellular models alone, or in combination
with microfluidic devices or mouth-to-airway transit models,
has increased in our knowledge of cellular behavior following
exposure to inhaled compounds. However, cell-based approaches
alone or integrated, are unable to holistically mimic the structural
and mechanical diversity of a human lung that determine the
biological and physiological characteristics of respiration. While
the obvious solution is to go directly to in vivo rodent and pig
models, the translational data acquired from animal respiratory
disease models are limited in providing mechanistic insight
into human pathologies (Ware, 2008), highlighting the demand
for alternative research platforms that better recapitulate the
dynamic architecture and complex cellularity of a human lung.
Thus, inhaled drug delivery investigations conducted on whole
lung tissue (ex vivo) models permit a thorough understanding
drug behavior in vivo, as ex vivo lung tissue samples retain
in vivo airway structure, architecture, cellular heterogeneity and
importantly, the microenvironment.
ADVANCES IN ex vivo RESEARCH
MODELS OFFER TRANSLATIONAL
PRECLINICAL, THERAPEUTIC
RELEVANCE WHEN SCREENING NOVEL
INHALED THERAPIES
Ex vivo lung models provide opportunities to study the
performance and therapeutic efficacy of inhaled drugs in either
healthy or diseased lungs. As ex vivo lung models retain the
3-dimensional lung structure and native microenvironment (cell-
cell, cell-matrix interactions), ex vivo drug studies can specifically
investigate the role the in vivo lung environment plays in
determining drug transport kinetics, cytotoxicity and therapeutic
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efficacy. This next section of the review will focus on two ex vivo
models, precision-cut lung slices (PCLS) and isolated perfused
lungs (IPL) (summarized in Table 2).
Precision-Cut Lung Slices Maintain
Complex Multi-Dimensional and
Multi-Cellular Interactions to
Appropriately Determine in vivo
Therapeutic Efficacy
Precision-cut lung slices are sections harvested from lung tissue
immediately following post mortem, sliced (100–300 µm) and
submerged in culture media to retain functional physiological
and cellular interactions while maintaining anatomical and
structural diversity of a lung (Placke and Fisher, 1987; Liu
et al., 2019). This preservation of lung architecture provides
for a clinically relevant ex vivo respiratory platform to study
therapeutic efficacy and cytotoxicity. Thus, PCLS have emerged
as a powerful research tool and offer a more complex mechanistic
understanding of drug interactions with the multicellular and
multidimensional properties of a lung (Hess et al., 2016; Hansen
et al., 2016; Cedilak et al., 2019; Liu et al., 2019). In addition, PCLS
provide opportunities to assess preclinical, translational studies
that determine therapeutic concentrations and efficacies of drugs
delivered to different lung regions and have also allowed for
cross-species comparisons—with PCLS reportedly prepared from
a variety of species including rodent, sheep and human lung tissue
(Danov et al., 2018; Lehmann et al., 2018; Yilmaz et al., 2019).
PCLS have been utilized in studies as pre-validation platforms
to screen compound toxicity and drug efficacy (Hess et al.,
2016; Danov et al., 2018; Cedilak et al., 2019). Drug delivery
to ex vivo PCLS is often via submersion in drug-containing
medium (Nassimi et al., 2009; Neuhaus et al., 2013, 2014;
Paranjpe et al., 2013) or direct liquid infusion (via culture
medium) to the airway (Hess et al., 2016) as the ventilated
delivery of compounds (to mimic inhaled delivery) to PCLS
models is currently unattainable. To work around this limitation
of PCLS models, Nassimi et al. (2010) administered aerosolized
nanoparticles to live BALB/c mice using a jet-driven aerosol
generator in a closed Plexiglas box system, mice were then
sacrificed and PCLS were generated (Nassimi et al., 2010).
Cytotoxicity of PCLS models, regardless of the route of drug
delivery, can be assessed by measuring changes to mitochondrial
activity, metabolic activity, cytokine release, or imaging of
Live/Dead staining of the whole lung section (Nassimi et al.,
2010; Neuhaus et al., 2013, 2014; Paranjpe et al., 2013; Hess
et al., 2016). PCLS models have further been developed to
mimic the complex structure and function relationship of the
pulmonary system with connected heart and lung harvested from
mice and then sliced (Paranjpe et al., 2013). Paranjpe et al.
(2013) determined the therapeutic efficacy of nanoparticles with
loaded with Sildenafil (Viagra) as a novel inhalable treatment of
pulmonary hypertension. Exposure of the formulated Sildenafil-
loaded SLN solutions to the heart and lung slices showed
that the IC50 value for lung slices was higher than that of
heart slices, suggesting that directly targeting the lungs with
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efficacy in the heart and relieve pulmonary hypertension
(Paranjpe et al., 2013).
The use of ex vivo PCLS models to determine in vivo
toxicities and therapeutic efficacies are a clinically relevant, pre-
validation research platform. As PLCS models consist of whole
lung tissue and maintain the complex multi-dimensional and
multi-cellular interactions of respiratory, immune and neuronal
cells, PCLS models are better placed to properly mimic a
therapeutic response to a delivered drug. While PCLS have
obvious limitations, namely the inability to mimic ventilation,
mechanical stretch or perfusion, this model has been successfully
used to determine the preclinical pharmacotoxicology and
therapeutic efficacy of novel compounds within an in vivo
environment (Liu et al., 2019). However, to study the region-
specific deposition of inhaled drugs and subsequent transport
analysis, an alternative model(s) is required to obtain greater
clinical relevance.
Isolated Perfused Lungs Are a Unique
Platform to Determine Inhaled Drug
Aerodynamic Performance and
Bio-Pharmacokinetics
Isolated perfused lungs are prepared by encasing the whole
lung of a rodent or rabbit within an artificial thoracic chamber
at physiologically relevant conditions (37◦C, 5% CO2) and
supplying a perfusion buffer (termed perfusate) to mimic
pulmonary circulation and ensure the sustained tissue survival
and function. In IPL ex vivo models, drug agents can be
administered directly into the lungs using inhalable delivery
systems such as nebulizers, modified nebulizers (AeroProbe),
aerosolizers (DustGun) or syringe insufflator (MicroSprayer,
PennCentury) (Tronde et al., 2002; Gerde et al., 2004; Ewing
et al., 2008; Beck-Broichsitter et al., 2010; Selg et al., 2013)
to replicate trachea-to-airway drug transit. However, when
replicating mouth-to-airway drug transit in IPL models, delivery
devices are limited due to the differences in the oral pharyngeal
anatomy between humans and animals. Furthermore, the device
selected for inhaled drug delivery or aerosolization are as equally
important as the physiochemical properties of the formulation
when determining aerosol performance, deposition and efficacy.
Nevertheless, ex vivo IPL offers a unique opportunity to test
inhaled drug delivery in a platform that is physiologically and
biologically similar to a human lung allowing drug aerodynamic
and bio-pharmacokinetic parameters to be studied.
IPL models are used to determine the uptake of inhaled
agents across the pulmonary epithelium, the subsequent rate
of drug absorption and therapeutic efficacy (Hochhaus et al.,
1997; Bosquillon et al., 2017; Eriksson et al., 2018). IPL has
been used to explore the drug transport profiles of inhaled
(ventilated)/nebulized compounds, or nanoparticles, that have
been formulated to achieve deposition in the tracheal, bronchial
or alveolar lung regions with high drug permeability, absorption
and retention (Tronde et al., 2002; Ewing et al., 2006; Beck-
Broichsitter et al., 2009; Selg et al., 2013; Eriksson et al., 2020). IPL
platforms have also integrated sophisticated imaging techniques
(photon correlation spectroscopy, laser Doppler anemometry,
atomic force microscopy and fluorescence spectroscopy) to
allow real-time analysis of drug stability during nebulization,
distribution profiles after nebulization (Beck-Broichsitter et al.,
2009), further validating IPL as a useful preclinical model for
screening novel inhaled drugs.
IPL models are typical of rodent or rabbit origin and
it is important that users are aware of the differences in
tracheobronchial anatomical and structural composition between
animal and human lungs. Not only do the airway diameters of
rodent lungs differ to that of human lungs, but rodent lungs
are monopodial with asymmetrical branching, while human
lungs are dichotomous with symmetrical branching (Phalen
et al., 1978; Yeh et al., 1979). While these differences in airway
structure have obvious implications for modeling the delivery
and deposition of inhaled compounds (Hofmann et al., 1989),
IPL offer a generalized understanding of inhaled drug behavior
within branched luminal space. It is important to note that
IPL models are unable to replicate the initial drug transit
mechanisms specifically, inhalation via the oral pharyngeal orifice
thus, IPL offers a physiologically relevant platform of the tracheal,
bronchial and alveolar regions to screen novel inhaled therapies.
Research platforms used to screen novel inhaled therapeutic
compounds, inherently suggests that the research is focused
toward finding a treatment for a specific disease or disease
phenotype. Yet interestingly, the vast majority of research
conducted that utilize IPL as a research tool are conducted
on healthy animal lungs. It has long been established that the
structural and mechanical properties of diseased lungs alter
not only the biological and physiological environment but
also the lung capacity (the volume of air able to be inspired
and expired) of individuals (Bates et al., 2007). For example,
emphysema patients have a significantly reduced lung capacity
as a result of the progressive destruction of alveolar spaces and
structural properties of the lungs. Therefore, is it important
that the relevant mechanical, structural and physiological
characteristics of the disease are appropriately modeled to obtain
appropriate aerodynamic and bio-pharmacokinetic information
when screening preclinical, inhaled therapies.
CONCLUSION
There is currently no single faultless universal model for
evaluating the delivery, efficacy and toxicity of inhaled therapies
thus, a single preclinical model cannot be advocated. The use
of multiple, relevant experimental approaches to screen inhaled
therapies is essential for the translation of preclinical inhaled
drug candidates to clinical practice. The ideal scientific strategy
is influenced by numerous factors including the physicochemical
properties of the drug, the disease of interest, and the
available laboratory resources. Furthermore, when selecting an
appropriate model, researchers must understand the limitations
and capabilities of in vitro and/or ex vivo platforms to be
implemented in their study. It is therefore critical to understand
both the benefits and drawbacks of each scientific platform
to appropriately answer the specific research question and
to maximize the relevance of the results obtained. Thus, the
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implementation of multiple experimental platforms provides for
greater relevance and validation of models for clinical relevance.
The predictive power of in vitro and ex vivo correlations for
preclinical inhaled therapies has been extensively reviewed in
the literature (Sakagami, 2006, 2020; Nahar et al., 2013; Nickel
et al., 2016; Ehrmann et al., 2020) and comparisons of in vitro
and ex vivo data have been used to establish, validate and
compare experimental models with known in vivo responses
(Sakagami, 2006, 2020; Nahar et al., 2013; Nickel et al., 2016;
Ehrmann et al., 2020). The most common in vivo tool used for
comparative inhaled therapy studies to date is the ALI culture
model, while the most common complementary ex vivo model
is the IPL platform, with studies demonstrating results that are
comparable to in vivo data (Nassimi et al., 2010; Ong et al.,
2014; Bosquillon et al., 2017). The in vivo predictive capabilities
of in vitro and ex vivo methodologies when performed side-
by-side have the potential to enhance novel drug screening
platforms and bridge the translation from preclinical testing to
the patient population. Innovative drug screening platforms can
accelerate and facilitate preclinical therapeutic studies to allow for
more informed decisions on potential inhalation drug candidates
for future use in clinical trials. Thus, the rapidly evolving and
innovative research space of 3D in vitro and ex vivo platforms to
model respiratory diseases and evaluate the therapeutic potential
of inhalation drug candidates provides promising avenue for
screening preclinical inhaled therapies.
AUTHOR CONTRIBUTIONS
AC and PB prepared the manuscript. AC and HO prepared
tables and figures. HO, PB, and DT provided critical feedback as
all authors contributed equally towards conceptualization of the
finalized manuscript.
REFERENCES
Aun, M. V., Bonamichi-Santos, R., Arantes-Costa, F. M., Kalil, J., and Giavina-
Bianchi, P. (2017). Animal models of asthma: utility and limitations. J. Asthma
Allergy 10, 293–301. doi: 10.2147/jaa.S121092
Barkauskas, C. E., Chung, M. I., Fioret, B., Gao, X., Katsura, H., and Hogan, B. L.
(2017). Lung organoids: current uses and future promise. Development 144,
986–997. doi: 10.1242/dev.140103
Bates, J. H., Davis, G. S., Majumdar, A., Butnor, K. J., and Suki, B. (2007). Linking
parenchymal disease progression to changes in lung mechanical function by
percolation. Am. J. Respir. Crit. Care Med. 176, 617–623. doi: 10.1164/rccm.
200611-1739OC
Beck-Broichsitter, M., Gauss, J., Gessler, T., Seeger, W., Kissel, T., and
Schmehl, T. (2010). Pulmonary targeting with biodegradable salbutamol-
loaded nanoparticles. J. Aerosol. Med. Pulm. Drug Deliv. 23, 47–57. doi: 10.1089/
jamp.2009.0759
Beck-Broichsitter, M., Gauss, J., Packhaeuser, C. B., Lahnstein, K., Schmehl,
T., Seeger, W., et al. (2009). Pulmonary drug delivery with aerosolizable
nanoparticles in an ex vivo lung model. Int. J. Pharm. 367, 169–178. doi: 10.
1016/j.ijpharm.2008.09.017
Benam, K. H., Villenave, R., Lucchesi, C., Varone, A., Hubeau, C., Lee, H. H., et al.
(2016). Small airway-on-a-chip enables analysis of human lung inflammation
and drug responses in vitro. Nat. Methods 13, 151–157. doi: 10.1038/nmeth.
3697
Berkers, G., van Mourik, P., Vonk, A. M., Kruisselbrink, E., Dekkers, J. F., de
Winter-de Groot, K. M., et al. (2019). Rectal organoids enable personalized
treatment of cystic fibrosis. Cell. Rep. 26, 1701.e3–1708.e3. doi: 10.1016/j.celrep.
2019.01.068
Borghardt, J. M., Kloft, C., and Sharma, A. (2018). Inhaled therapy in respiratory
disease: the complex interplay of pulmonary kinetic processes. Can. Respir. J.
2018:2732017. doi: 10.1155/2018/2732017
Bosquillon, C., Madlova, M., Patel, N., Clear, N., and Forbes, B. (2017). A
comparison of drug transport in pulmonary absorption models: isolated
perfused rat lungs, respiratory epithelial cell lines and primary cell culture.
Pharm. Res. 34, 2532–2540. doi: 10.1007/s11095-017-2251-y
Bovard, D., Sandoz, A., Luettich, K., Frentzel, S., Iskandar, A., Marescotti, D., et al.
(2018). A lung/liver-on-a-chip platform for acute and chronic toxicity studies.
Lab. Chip. 18, 3814–3829. doi: 10.1039/c8lc01029c
Cedilak, M., Banjanac, M., Belamarić, D., Paravić Radičević, A., Faraho, I., Ilić,
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Kreft, M. E., Jerman, U. D., Lasič, E., Hevir-Kene, N., Rižner, T. L., Peternel, L.,
et al. (2015). The characterization of the human cell line Calu-3 under different
culture conditions and its use as an optimized in vitro model to investigate
bronchial epithelial function. Eur. J. Pharm. Sci. 69, 1–9. doi: 10.1016/j.ejps.
2014.12.017
Kumar, V., Bariwal, J., Narang, A. S., Tso, J., Cheong, J., and Mahato, R. I. (2020).
Functional similarity of modified cascade impactor to deposit drug particles on
cells. Int. J. Pharm. 583:119404. doi: 10.1016/j.ijpharm.2020.119404
Latvala, S., Hedberg, J., Möller, L., Odnevall Wallinder, I., Karlsson, H. L., and
Elihn, K. (2016). Optimization of an air-liquid interface exposure system for
assessing toxicity of airborne nanoparticles. J. Appl. Toxicol. 36, 1294–1301.
doi: 10.1002/jat.3304
Leeman, K. T., Pessina, P., Lee, J. H., and Kim, C. F. (2019). Mesenchymal stem
cells increase alveolar differentiation in lung progenitor organoid cultures. Sci.
Rep. 9:6479. doi: 10.1038/s41598-019-42819-1
Lehmann, M., Buhl, L., Alsafadi, H. N., Klee, S., Hermann, S., Mutze, K., et al.
(2018). Differential effects of Nintedanib and Pirfenidone on lung alveolar
epithelial cell function in ex vivo murine and human lung tissue cultures of
pulmonary fibrosis. Respir. Res. 19:175. doi: 10.1186/s12931-018-0876-y
Li, F., He, J., Wei, J., Cho, W. C., and Liu, X. (2015). Diversity of epithelial stem cell
types in adult lung. Stem Cells Int. 2015:728307. doi: 10.1155/2015/728307
Lippmann, M., Yeates, D. B., and Albert, R. E. (1980). Deposition, retention, and
clearance of inhaled particles. Br. J. Ind. Med. 37, 337–362. doi: 10.1136/oem.
37.4.337
Liu, G., Betts, C., Cunoosamy, D. M., Åberg, P. M., Hornberg, J. J., Sivars, K. B.,
et al. (2019). Use of precision cut lung slices as a translational model for the
study of lung biology. Respir. Res. 20:162. doi: 10.1186/s12931-019-1131-x
Liu, Z., Anderson, J. D., Deng, L., Mackay, S., Bailey, J., Kersh, L., et al. (2020).
Human nasal epithelial organoids for therapeutic development in cystic fibrosis.
Genes 11:603. doi: 10.3390/genes11060603
Madara, J. L. (1998). Regulation of the movement of solutes across tight junctions.
Annu. Rev. Physiol. 60, 143–159. doi: 10.1146/annurev.physiol.60.1.143
Marple, V. A., Olson, B. A., Santhanakrishnan, K., Mitchell, J. P., Murray, S. C.,
and Hudson-Curtis, B. L. (2003a). Next generation pharmaceutical impactor (a
new impactor for pharmaceutical inhaler testing). Part II: archival calibration.
J. Aerosol. Med. 16, 301–324. doi: 10.1089/089426803769017668
Marple, V. A., Olson, B. A., Santhanakrishnan, K., Roberts, D. L., Mitchell, J. P.,
and Hudson-Curtis, B. L. (2004). Next generation pharmaceutical impactor: a
new impactor for pharmaceutical inhaler testing. Part III. extension of archival
calibration to 15 L/min. J. Aerosol. Med. 17, 335–343. doi: 10.1089/jam.2004.17.
335
Marple, V. A., Roberts, D. L., Romay, F. J., Miller, N. C., Truman, K. G., Van Oort,
M., et al. (2003b). Next generation pharmaceutical impactor (a new impactor
for pharmaceutical inhaler testing). part I: design. J. Aerosol. Med. 16, 283–299.
doi: 10.1089/089426803769017659
Mendes, P. J., Sousa, J. M., and Pinto, J. F. (2009). Prediction of the deposition of
dry powder aerosols. AAPS J. 11, 186–194. doi: 10.1208/s12248-009-9095-2
Miller, A. J., Dye, B. R., Ferrer-Torres, D., Hill, D. R., Overeem, A. W., Shea, L. D.,
et al. (2019). Generation of lung organoids from human pluripotent stem cells
in vitro. Nat. Protoc. 14, 518–540. doi: 10.1038/s41596-018-0104-8
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 13 October 2020 | Volume 8 | Article 581995
fbioe-08-581995 October 19, 2020 Time: 19:14 # 14
Cidem et al. Advancements in Inhalation Drug Screening
Miller, P. G., Chen, C. Y., Wang, Y. I., Gao, E., and Shuler, M. L. (2020).
Multiorgan microfluidic platform with breathable lung chamber for inhalation
or intravenous drug screening and development. Biotechnol. Bioeng. 117, 486–
497. doi: 10.1002/bit.27188
Molina, S. A., Stauffer, B., Moriarty, H. K., Kim, A. H., McCarty, N. A., and Koval,
M. (2015). Junctional abnormalities in human airway epithelial cells expressing
F508del CFTR. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L475–L487. doi:
10.1152/ajplung.00060.2015
Monnappa, A. K., Bari, W., Choi, S. Y., and Mitchell, R. J. (2016). Investigating
the responses of human epithelial cells to predatory bacteria. Sci. Rep. 6:33485.
doi: 10.1038/srep33485
Movia, D., Bazou, D., Volkov, Y., and Prina-Mello, A. (2018). Multilayered
Cultures of NSCLC cells grown at the Air-Liquid Interface allow the efficacy
testing of inhaled anti-cancer drugs. Sci. Rep. 8:12920. doi: 10.1038/s41598-018-
31332-6
Nahar, K., Gupta, N., Gauvin, R., Absar, S., Patel, B., Gupta, V., et al. (2013).
In vitro, in vivo and ex vivo models for studying particle deposition and drug
absorption of inhaled pharmaceuticals. Eur. J. Pharm. Sci. 49, 805–818. doi:
10.1016/j.ejps.2013.06.004
Nassimi, M., Schleh, C., Lauenstein, H. D., Hussein, R., Hoymann, H. G., Koch,
W., et al. (2010). A toxicological evaluation of inhaled solid lipid nanoparticles
used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm.
75, 107–116. doi: 10.1016/j.ejpb.2010.02.014
Nassimi, M., Schleh, C., Lauenstein, H. D., Hussein, R., Lübbers, K., Pohlmann,
G., et al. (2009). Low cytotoxicity of solid lipid nanoparticles in in vitro
and ex vivo lung models. Inhal. Toxicol. 21(Suppl. 1), 104–109. doi: 10.1080/
08958370903005769
Neuhaus, V., Chichester, J. A., Ebensen, T., Schwarz, K., Hartman, C. E., Shoji,
Y., et al. (2014). A new adjuvanted nanoparticle-based H1N1 influenza vaccine
induced antigen-specific local mucosal and systemic immune responses after
administration into the lung. Vaccine 32, 3216–3222. doi: 10.1016/j.vaccine.
2014.04.011
Neuhaus, V., Schwarz, K., Klee, A., Seehase, S., Förster, C., Pfennig, O., et al.
(2013). Functional testing of an inhalable nanoparticle based influenza vaccine
using a human precision cut lung slice technique. PLoS One 8:e71728. doi:
10.1371/journal.pone.0071728
Nickel, S., Clerkin, C. G., Selo, M. A., and Ehrhardt, C. (2016). Transport
mechanisms at the pulmonary mucosa: implications for drug delivery. Expert
Opin. Drug Deliv. 13, 667–690. doi: 10.1517/17425247.2016.1140144
Ong, H. X., Benaouda, F., Traini, D., Cipolla, D., Gonda, I., Bebawy, M., et al.
(2014). In vitro and ex vivo methods predict the enhanced lung residence
time of liposomal ciprofloxacin formulations for nebulisation. Eur. J. Pharm.
Biopharm. 86, 83–89. doi: 10.1016/j.ejpb.2013.06.024
Ong, H. X., Jackson, C. L., Cole, J. L., Lackie, P. M., Traini, D., Young, P. M.,
et al. (2016). Primary air-liquid interface culture of nasal epithelium for nasal
drug delivery. Mol. Pharm. 13, 2242–2252. doi: 10.1021/acs.molpharmaceut.5b
00852
Ong, H. X., Traini, D., Bebawy, M., and Young, P. M. (2011). Epithelial profiling
of antibiotic controlled release respiratory formulations. Pharm. Res. 28, 2327–
2338. doi: 10.1007/s11095-011-0462-1
Ong, H. X., Traini, D., Loo, C. Y., Sarkissian, L., Lauretani, G., Scalia, S., et al.
(2015). Is the cellular uptake of respiratory aerosols delivered from different
devices equivalent? Eur. J. Pharm. Biopharm. 93, 320–327. doi: 10.1016/j.ejpb.
2015.04.012
Palumbo, M. O., Kavan, P., Miller, W. H. Jr., Panasci, L., Assouline, S., Johnson,
N., et al. (2013). Systemic cancer therapy: achievements and challenges that lie
ahead. Front. Pharmacol. 4:57. doi: 10.3389/fphar.2013.00057
Paolicelli, G., Luca, A., Jose, S. S., Antonini, M., Teloni, I., Fric, J., et al. (2019). Using
lung organoids to investigate epithelial barrier complexity and IL-17 signaling
during respiratory infection. Front. Immunol. 10:323. doi: 10.3389/fimmu.2019.
00323
Paranjpe, M., Neuhaus, V., Finke, J. H., Richter, C., Gothsch, T., Kwade, A., et al.
(2013). In vitro and ex vivo toxicological testing of sildenafil-loaded solid lipid
nanoparticles. Inhal. Toxicol. 25, 536–543. doi: 10.3109/08958378.2013.810315
Pezzulo, A. A., Starner, T. D., Scheetz, T. E., Traver, G. L., Tilley, A. E., Harvey,
B. G., et al. (2011). The air-liquid interface and use of primary cell cultures are
important to recapitulate the transcriptional profile of in vivo airway epithelia.
Am. J. Physiol. Lung Cell. Mol. Physiol. 300, L25–L31. doi: 10.1152/ajplung.
00256.2010
Phalen, R. F., Yeh, H. C., Schum, G. M., and Raabe, O. G. (1978). Application of
an idealized model to morphometry of the mammalian tracheobronchial tree.
Anat. Rec. 190, 167–176. doi: 10.1002/ar.1091900202
Placke, M. E., and Fisher, G. L. (1987). Adult peripheral lung organ culture–a
model for respiratory tract toxicology. Toxicol. Appl. Pharmacol. 90, 284–298.
doi: 10.1016/0041-008x(87)90336-x
Qi, A., Friend, J. R., Yeo, L. Y., Morton, D. A., McIntosh, M. P., and Spiccia,
L. (2009). Miniature inhalation therapy platform using surface acoustic wave
microfluidic atomization. Lab. Chip 9, 2184–2193. doi: 10.1039/b903575c
Ren, H., Birch, N. P., and Suresh, V. (2016). An optimised human cell culture model
for alveolar epithelial transport. PLoS One 11:e0165225. doi: 10.1371/journal.
pone.0165225
Ruge, C. A., Kirch, J., and Lehr, C. M. (2013). Pulmonary drug delivery: from
generating aerosols to overcoming biological barriers-therapeutic possibilities
and technological challenges. Lancet Respir. Med. 1, 402–413. doi: 10.1016/
s2213-2600(13)70072-9
Sakagami, M. (2006). In vivo, in vitro and ex vivo models to assess pulmonary
absorption and disposition of inhaled therapeutics for systemic delivery. Adv.
Drug Deliv. Rev. 58, 1030–1060. doi: 10.1016/j.addr.2006.07.012
Sakagami, M. (2020). In vitro, ex vivo and in vivo methods of lung absorption for
inhaled drugs. Adv. Drug Deliv. Rev. 58, 9–10. doi: 10.1016/j.addr.2020.07.025
Salomon, J. J., Muchitsch, V. E., Gausterer, J. C., Schwagerus, E., Huwer, H., Daum,
N., et al. (2014). The cell line NCl-H441 is a useful in vitro model for transport
studies of human distal lung epithelial barrier. Mol. Pharm. 11, 995–1006.
doi: 10.1021/mp4006535
Selg, E., Ewing, P., Acevedo, F., Sjöberg, C. O., Ryrfeldt, A., and Gerde, P. (2013).
Dry powder inhalation exposures of the endotracheally intubated rat lung,
ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate.
J. Aerosol. Med. Pulm. Drug Deliv. 26, 181–189. doi: 10.1089/jamp.2012.0971
Sheikh, Z., Bradbury, P., Pozzoli, M., Young, P. M., Xin Ong, H., and Traini,
D. (2020). An in vitro model for assessing drug transport in cystic fibrosis
treatment: characterisation of the CuFi-1 cell line. Eur. J. Pharm. Biopharm. 156,
121–130. doi: 10.1016/j.ejpb.2020.09.002
Shur, J., and Price, R. (2016). Predictive in vitro dissolution methods for orally
inhaled drug products. Respir. Drug Deliv. 1121–130.
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